Reaping in due season? R&D trends and novel drug launches
This article was originally published in Scrip
In the fashion world, hemlines drop at the first hint of a recession, but seasons in pharmaceutical R&D are more reminiscent of those in the A Game of Thrones’ mythical land of Westeros – they change very slowly.
You may also be interested in...
Positive Phase II data for Aptinyx’s novel NMDA receptor modulator are strong enough to take the product into a pivotal study in this difficult-to-treat area.
Orchard Therapeutics is on the cusp of the first approval for its ex vivo gene therapy, Libmeldy, for metachromatic leukodystrophy.
Gilead/Kite’s second CAR-T product is given the go-ahead for approval by the CHMP for mantle cell lymphoma.